Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ABG enters its October 27 earnings with a stark gap between where analysts set their targets just weeks ago and where the stock is trading today.
The most striking development this week is a wave of target-price cuts from major firms, all arriving within three days of each other. UBS's Joseph Spak trimmed his target from $250 to $193 on October 7. Morgan Stanley's Daniela Haigian cut from $230 to $184 on October 5. JP Morgan's Rajat Gupta, already bearish with an Underweight rating, shaved his target from $190 to $185. Barclays lowered from $265 to $230. Every major firm that touched the stock this week went lower, none changed their rating, and none turned positive. The mean consensus target now stands at $245, against a close of $169.76, a spread that looks generous given the direction of travel. The stock has dropped 22% over the past month, and was off another 2.4% this week alone.
The bull and bear cases are not close. Bears point to same-store performance that has lagged the dealership group for three straight years, a forecast 7% EPS decline in 2026 that would be the worst in the peer group, and Tekion DMS transition costs still running through the P&L. The bull case rests on operating leverage: management is guiding SG&A as a percentage of gross profit below 64% by year-end from 68.6% in Q1, and every 1% of improvement is worth roughly $30 million and $1.20 in EPS. The Tekion rollout now covers more than half of ABG's 158 stores. On valuation, the stock trades at roughly 5.9x trailing earnings and 0.67x book, with an EV/EBITDA of 9.4x. The forward earnings growth factor sits in the 84th percentile of the universe, though the analyst recommendation divergence score at 94 reflects just how far apart the Street is on the name.
Positioning in the lending market gives shorts no particular edge. Short interest has been climbing over the past month, up around 11.6% in 30 days to roughly 6.4% of the free float. But the borrow market is exceptionally loose. Availability is running near 3,787%, meaning shares to borrow dwarf the existing short position by a wide margin. Cost to borrow is 0.47%, down 8% on the week and at its lowest level since August. There is no squeeze dynamic here. The options market is similarly unthreatening to bears: the put/call ratio is 0.16, well below its 20-day average of 0.13, and z-score of 0.87 points to no unusual defensive hedging. The short score of 48.3 is roughly neutral and has barely moved in two weeks.
One genuinely notable holder is Impactive Capital LP, which filed a Schedule 13D in January 2025 and has since trimmed its stake from 6.3% to 4.8% as of its July 2026 amendment, the most recent on record. Impactive filed under 13D, signalling activist intent, and its reduction is worth watching. As last disclosed, its position sits just below the 5% threshold, and holders who fall below that level have no obligation to file further updates. BlackRock remains the largest holder at around 16.4% of shares, and added a modest 59,759 shares in the quarter ending September 30. Among peers, AN fell 2.2% on the day while GPI dropped 1.9%, suggesting sector-wide pressure rather than ABG-specific selling, though ABG's 22% monthly loss is materially steeper than most of the group.
Retail attention has spiked: the Wikipedia views mover signal is running at a z-score of 2.5 against ABG's own 90-day history as of late September, one of the higher attention readings in the dataset. That is an attention signal, not a revenue indicator, but it suggests the name is drawing more eyes than usual, likely in response to the price slide. With earnings on October 27, the next three weeks become less about whether SG&A guidance holds and more about whether management can persuade investors that the Tekion costs are genuinely transitory and the margin roadmap survives a softer macro.
See the live data behind this article on ORTEX.
Open ABG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.